Interferon Beta
Relevant Publications
Nebulised interferon beta-1a (SNG001) in hospitalised COVID-19: SPRINTER Phase III Study A Game of Infection – Song of Respiratory Viruses and Interferons Dynamics of SARS-CoV-2 shedding in the respiratory tract depends on the severity of disease in COVID-19 patients Safety and efficacy of inhaled nebulized interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomized, double-blind, placebo-controlled, phase 2 trial Treatment of SARS with human interferons Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients Antiviral activities of type I interferons to SARS-CoV-2 infection Upper airway gene expression reveals suppressed immune responses to SARS-CoV-2 compared with other respiratory viruses Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling Autoantibodies against type I IFNs in patients with life-threatening COVID-19 Immunology of COVID-19: Current State of the Science The Effect of Inhaled IFN-β on Worsening of Asthma Symptoms Caused by Viral Infections. A Randomized Trial Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19
